# EDGAR Filing Document

**Accession Number:** 0001472012
**File Stem:** 0001104659-23-001704
**Filing Date:** 2023-1
**Character Count:** 40131
**Document Hash:** 2d4fe1bbae4bcffe4afa09d387d25934
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-001704.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0001104659-23-001704

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 47

**CONFORMED PERIOD OF REPORT**: 20230104

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immunome Inc.
- **CENTRAL INDEX KEY:** 0001472012
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 770694340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39580
- **FILM NUMBER:** 23513783

**BUSINESS ADDRESS:**
- **STREET 1:** 665 STOCKTON DRIVE
- **STREET 2:** SUITE 300
- **CITY:** EXTON
- **STATE:** PA
- **ZIP:** 19341
- **BUSINESS PHONE:** 610-321-3700

**MAIL ADDRESS:**
- **STREET 1:** 665 STOCKTON DRIVE
- **STREET 2:** SUITE 300
- **CITY:** EXTON
- **STATE:** PA
- **ZIP:** 19341

?xml version="1.0" encoding="utf-8"?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

------

**FORM 8-K**

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): January 4, 2023**

------

**Immunome, Inc.**

**(Exact name of registrant as specified in its charter)**

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39580** | **77-0694340** |
| **(state or other jurisdiction <br> of incorporation)** | **(Commission <br> File Number)** | **(I.R.S. Employer <br> Identification No.)** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**665 Stockton Drive, Suite 300 <br> Exton, Pennsylvania** | &nbsp;&nbsp;**19341** |
| &nbsp;&nbsp;**(Address of principal executive offices)** | &nbsp;&nbsp;**(Zip Code)** |

---

**Registrant's telephone number, including area code: (610** **) 321-3700**

**Not applicable**

**(Former name or former address, if changed since last report.)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class | Name of each exchange<br> on which registered |
| **Common Stock, $0.0001 par value per share** **IMNM** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement.** |

---

On November 17, 2022, Immunome, Inc. (the "Company") entered into a Letter Agreement ("Letter Agreement") with the Whitehead Institute for Biomedical Research ("Whitehead"), which became effective on January 4, 2023 upon the satisfaction of the conditions described therein. The Letter Agreement supplements the Exclusive Patent License Agreement entered into between the Company and Whitehead on June 25, 2009 (as amended on December 17, 2009, March 21, 2013, August 21, 2017 and July 21, 2020, the "License Agreement"). Pursuant to the Letter Agreement, Whitehead and the Company agreed that certain payments received by the Company from the Collaborator (as defined in the Letter Agreement) (i.e., a "corporate partner," as defined in the License Agreement) would be excluded from the Company's payment obligations to Whitehead. The Company and Whitehead further agreed, among other things, that the Company will make certain payments to Whitehead (i) as Net Sales (as defined in the License Agreement) as long as the Company receives those payments from the Collaborator on a specified number of products purchased by the Collaborator and (ii) upon the achievement of certain milestones whether by the Company or the Collaborator.

The foregoing description is not complete and is qualified in its entirety by reference to the full text of the Letter Agreement which the Company intends to file with the U.S. Securities and Exchange Commission with its Annual Report on Form 10-K for the year ended December 31, 2022. The License Agreement was previously filed as Exhibit 10.11 to the Company's Annual Report on Form 10-K for the year ended December 31, 2021.

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

*<u>IMM-BCP-01 Update</u>*

 

On January 6, 2023, the Company announced that it successfully completed dosing of the first cohort of patients in a Phase 1b study of IMM-BCP-01, its COVID-19 antibody cocktail, with no significant treatment-related adverse events. The Company has decided to seek a partner in order to continue the trial and for any further development activities.

*<u>Corporate Presentation</u>*

On January 6, 2023, the Company posted a presentation to its website that may be used by the Company from time to time in meetings with investors, analysts, collaborators, vendors or other third parties. A copy of the presentation is attached as Exhibit 99.1 to this report and incorporated into this Item 8.01 by reference.

The information disclosed under the heading "Corporate Presentation" in this Item 8.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| [99.1](tm231749d1_ex99-1.htm) | [Presentation dated January 2023.](tm231749d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **IMMUNOME, INC.** | **IMMUNOME, INC.** |
| By: | /s/ Purnanand D. Sarma, Ph.D. |
|  | Purnanand D. Sarma, Ph.D. |
|  | President and Chief Executive Officer |

---

Dated: January 6, 2023

## Exhibit 99.1

**Exhibit 99.1**

![](tm231749d1_ex99-1img001.jpg)

Harnessing the Power of the Human Memory B Cell JANUARY 2023 Immunome, Inc. 665 Stockton Drive, Suite 300 \| Exton, PA 19341 610.321.3700 \| immunome.com Copyright© 2023 Immunome, Inc. All rights reserved.

![](tm231749d1_ex99-1img002.jpg)

2 Disclaimers and Forward - Looking Statements Copyright© 2023 Immunome, Inc. All rights reserved. This presentation includes certain disclosures that contain "forward - looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding our beliefs and expectations regarding the advancement of our oncology and infectious disease programs and platform, execution of our regulatory, clinical and strategic plans, therapeutic potential and benefits of our programs and anticipated upcoming milestones for our programs, as well as the timing and progress of each of the foregoing matters. Forward - looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "suggest," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward - looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the following: our ability to execute on our strategy, including with respect to R&D efforts, IND submissions and other regulatory filings, timing of these filings and the timing and nature of governmental authority feedback regarding the same, initiation and completion of any clinical studies, confirmatory testing and other anticipated milestones as and when anticipated; the fact that research and development data are subject to differing interpretations and assessments, including during the peer review/publication process in the scientific community and by regulatory authorities; whether our data will be published in a scientific journal and, if so, when and with what modifications; the effectiveness of our product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with earlier - published data and/or data used for advancing the product candidates; the fact that changes in the profile of the diseases that our programs target could emerge that could impact our ability to address those changes; our ability to fund operations; our reliance on vendors; our ability to execute on our plans for collaborations and partnerships; the competitive landscape; the impact of the COVID - 19 pandemic on our business, operations, strategy, goals and anticipated milestones; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10 - K filed with the United States Securities and Exchange Commission (SEC) on March 28, 2022, and elsewhere in Immunome's Quarterly Reports on form 10 - Q and other filings and reports with the SEC. All statements contained in this presentation are made as of the date specified on the cover, and we undertake no duty to publicly update or revise any such statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. This presentation may contain product names, trade names, trademarks and service marks of Immunome and of other organizations, which are the properties of their respective owners. Statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this presentation, including independent market research, industry publications and surveys, governmental agency publications and other publicly available information. While we believe that information provides a reasonable basis for these statements, it may be limited or incomplete and we may have not independently verified it. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all relevant information. We make statements and predictions about future dates for achievement of milestones related to our platform and our programs in this presentation. These statements and predictions involve risks and uncertainties based on various factors and evolution over time and, therefore, actual dates for these milestones may differ. In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind.

![](tm231749d1_ex99-1img003.jpg)

Immunome "At a Glance" Disruptive Technology Leveraging Human Immune Response 3 Copyright© 2023 Immunome, Inc. All rights reserved. → Interrogates memory B cells, the most educated component of the human immune system → Potential across multiple therapeutic areas Patient Informed Drug Discovery Engine → AbbVie multi - year research collaboration (up to 10 novel antibody - target pairs) → U.S. DoD JPEO - CBRND in collaboration with DHA (Antibody cocktail for SARS - CoV - 2) Significant Partnering Potential → Antibody targeting IL - 38, a novel context dependent immune modulator in multiple solid tumors with poor prognosis → IND submission anticipated mid - 2023 Lead Oncology Program IMM - ONC - 01 → Antibody targeting EPN1, an ectopically expressed target → Multiple additional novel targets enabling next - generation modalities (ADCs, T - cell engagers) Rich Research Pipeline → Value creation through partnerships and proprietary programs → Strong cash position; runway through at least 3Q 2024 Capital - Efficient Business Strategy

![](tm231749d1_ex99-1img004.jpg)

Strategic Discovery Collaboration with AbbVie AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets 4 Copyright© 2023 Immunome, Inc. All rights reserved. → Immunome will grant AbbVie the option to purchase worldwide rights for up to 10 novel target - antibody pairs arising from three specified tumor types → Key Financial Terms – $30M upfront payment – Eligible for additional payments up to: – $70M platform access payments – Development and first commercial sale milestones of up to $120M per target – Further sales - based milestones – Tiered royalties on global sales Immunome's approach has the potential to unlock novel cancer biology and yield multiple therapeutic candidates STEVE DAVIDSEN VP, Oncology Discovery Research, AbbVie This collaboration with AbbVie, a true leader in the development and commercialization of oncology therapeutics, demonstrates the strength of Immunome's Discovery Engine PURNANAND SARMA President & CEO, Immunome

![](tm231749d1_ex99-1img005.jpg)

B cells: Critical Players in Immunity Oncology 5 Copyright© 2023 Immunome, Inc. All rights reserved. → B cell infiltration more closely associated with survival than T cell presence in multiple cancers → Success of I/O therapies appears to be associated with coordinated response including B cells and TLS in the unique context of each patient's tumor microenvironment → However, specificity of the B cell immune repertoire has not been explored beyond known tumor antigens Cabrita et al, Nature (2020) Survival in Melanoma Patients

![](tm231749d1_ex99-1img006.jpg)

Cataloging the Context - Dependent B - cell Response Against Cancer 6 Copyright© 2023 Immunome, Inc. All rights reserved. → Cancer cells modify their microenvironment to make it fertile ground for tumor growth → The human immune system makes a coordinated, time - dependent, attack against cancer in the context of that modified environment → T cell response has been the focus of drug development efforts in recent times. Clinical unmet need, however, remains high → Memory B cells record the targets that are identified as important attack points for antibodies across the course of tumor development, catalogued by Discovery Engine ANTIBODIES DENDRITIC CELL MACROPHAGE T CELL B CELL TUMOR MICROENVIRONMENT MISFOLDED PROTEIN ABBERANT GLYCOSYLATION NON - SILENT GENE MUTATIONS ECTOPIC EXPRESSION

![](tm231749d1_ex99-1img007.jpg)

We See the Disease Through the Lens of a Memory B - cell Interrogate Most Educated Components of Immune Response in an Unbiased Manner at Industrial Scale 7 Copyright© 2023 Immunome, Inc. All rights reserved. Antibody Screening Proprietary, multiplexed interrogation of patient B cell responses against authentic tumor antigen sources Immortalizing B - cell Response Proprietary hybridoma technology producing authentic antibodies from thousands of B - cells Antibody Validation Definitive target identification and characterization of antibody – target interactions Therapeutic Output Unique therapeutic antibody - target pairs Multiple Patients Ongoing access to new and diverse patient memory B cells Blood, Lymph nodes and tumor tissue Thousands of B - cells /patient Up to 20,000 antibodies and millions of data points per screen Canonical and non - canonical targets; identify on average 2 – 4 targets per patient Antibodies targeting novel, public antigens

![](tm231749d1_ex99-1img008.jpg)

Broad Applicability Across Therapeutic Areas Unbiased Interrogation Unveils Targets & Underexplored Biology: Examples 8 Copyright© 2023 Immunome, Inc. All rights reserved. Immunology: Conserved Epitopes Identification of antibodies specific for broadly conserved epitopes, including across species Infectious Disease: Multi - modal Action Unique insights into breadth of immune response against SARS - CoV - 2 by super responder patients Oncology: Target Rich Clusters Targets identified across patients with different tumors cluster around distinct areas of tumor biology Immune Modulation Novel Targets Discovery Engine Extracellular Matrix DiMuzio et al VaccineX 2021 Need a figure for this panel Knowles et al Nature Reviews Molecular Cell Biology (2014) https:// doi.org /10.1038/nrm3810

![](tm231749d1_ex99-1img009.jpg)

9 Platform has Potential for Diversified Partnering Strategy Across Therapeutic Areas Copyright© 2023 Immunome, Inc. All rights reserved. → $30M Upfront → $70M Platform Milestones → $120M/target Development and First Commercial Sale Milestones → Sales - based Milestones → Tiered Royalties on Global Sales IMM - BCP - 01 (SARS - CoV - 2 Antibody Cocktail) Anti - Infectives 01 Oncology Solid Tumors 02 03 04 05 → $17.6M non - dilutive funding (OTA: W911Q - Y - 20 - 9 - 0019) → Funded by U.S. DoD JPEO - CBRND in collaboration with DHA → Various Malignancies Oncology, Hematological → Auto - Immune Disorders → Immunology Immune Disorders → Neuroinflammation Neurology Up to 10 novel antibody - target pairs in 3 tumor types Potential Future Therapeutic Areas

![](tm231749d1_ex99-1img010.jpg)

Immunome Pipeline Targets Identified from Authentic Human Immune Response 10 Copyright© 2023 Immunome, Inc. All rights reserved. PROGRAM POTENTIAL DISEASE OF RELEVANCE STAGE NEXT MILESTONE IMM - BCP - 01 (Anti SARS - CoV - 2)\* Three antibody cocktail (multi - modal action, including neutralization and complement activation) COVID - 19 Phase 1b\* Actively exploring partnerships IMM - ONC - 01 (Anti - IL - 38) Soluble cytokine, Immune modulator Neutralize IL - 38; recruit and activate immune cells Squamous carcinomas of head & neck, gastroesophageal, lung Pre - clinical Development IND submission mid - 2023 IMM20059 (Anti - EPN1) Membrane Dynamics Ectopically expressed on cancer cells and exosomes; modulate receptor trafficking; reactivate exhausted anti - tumor T cells Melanoma, breast, lung, bladder, genitourinary, and liver cancers Target Research & Lead ID Lead nomination Undisclosed oncology targets Suitable for ADC and T Cell Engager Modalities Solid tumors Target Research & Lead ID Lead nomination RESEARCH CLINICAL \* We completed dosing of the first cohort of patients with no significant treatment - related adverse events. We have decided to s eek a partner in order to continue the trial and for any further development activities. See slide #33 for topline results.

![](tm231749d1_ex99-1img011.jpg)

Oncology Copyright© 2023 Immunome, Inc. All rights reserved.

![](tm231749d1_ex99-1img012.jpg)

Immunome's Discovery Engine Functional B - cell Interrogation to Actionable Public Targets 12 Copyright© 2023 Immunome, Inc. All rights reserved. Functional screening prioritizes patient - derived antibodies that bind to actionable public targets 03 Memory B Cells Represent One of the Most Educated Components of the Human Immune System Discovery Engine interrogates patient memory B cell responses in unbiased manner and at industrial scale 02 Tumor Types B cells identify important targets within the natural context of disease 01 Pero et al, Clin Trans Immunol (2022) Autologous Tumor binding Immunome Internal Data

![](tm231749d1_ex99-1img013.jpg)

Unveiling "Tumor Context" Novel Insights into Tumor Targets and Biological Processes 13 Copyright© 2023 Immunome, Inc. All rights reserved. Human immune system sees unique features of cancer cells → Mutations, Unexpected localization of proteins (ectopic expression) on tumor surface → Splice variants, post - translational modification Antibody responses across diverse cancers highlight common areas of target - rich biology → Multiple targets in the same biological pathway Highly productive platform identifies both validated and novel actionable cancer targets → Anti - ErbB2 Abs identified from patients with classically defined ErbB2 - driven and non - ErbB2 driven cancers → Expression linked to clinical outcomes (IL - 38) Disease Relevance Takeda et al. PLoS One (2017) ErbB2 Target - specific Literature Target Clusters

![](tm231749d1_ex99-1img014.jpg)

Discovery Engine Highlights Ectopically Expressed Targets A Novel Class of Targets with Potentially High Tumor Selectivity 14 Copyright© 2023 Immunome, Inc. All rights reserved. → Some proteins normally found intracellularly appear to be selectively located on the extracellular side of plasma membrane in cancer cells, and are seen as targets by the immune system → This ectopic cell surface expression may be used to selectively target tumor cells. Our Discovery Engine identifies ectopic targets and antibodies simultaneously → Represent a novel class of targets potentially suitable for development of next generation ADC (antibody - drug conjugate) and TCE (T cell engager) therapeutics High Throughput Functional Characterization: Proof of Concept

![](tm231749d1_ex99-1img015.jpg)

Example of an Ectopically Expressed Target as an ADC 15 Copyright© 2023 Immunome, Inc. All rights reserved. \*Immunome internal data 0 1 0 0 0 2 0 0 0 3 0 0 0 4 0 0 0 0 10 20 30 40 Raw Binding Signal S - S c o r e 17. PR121-00372 C11orf68 Target B Ab Highly Selective for Single Protein Target Selective Tumor Cell Binding High Tumor:Normal Cell Binding Ratio Tumor Normal 0 . 0 1 0 . 1 1 1 0 1 0 0 0 20 40 60 80 100 Log Conc. (nM) % C y t o t o x i c i t y Anti-C11orf68-VC-MMAF Cetuximab-VC-MMAF Trastuzumab-VC-MMAF anti-RSV-VC-MMAF free MMAF 0 . 0 1 0 . 1 1 1 0 1 0 0 0 20 40 60 80 100 Log Conc. (nM) % C y t o t o x i c i t y Antibody B -Vc-MMAF anti-RSV-Vc-MMAF Unconj. Vc-MMAF Cetuximab-Vc-MMAF Trastuzumab (Her2) Free MMAF Anti - RSV - VC - MMAF Antibody B - VC - MMAF Cetuximab (EGFR) - VC - MMAF Trastuzumab (Her2) - VC - MMAF Internalization Patient - derived Ab Suitable for ADC Format Neg Cntrl Antibody B

![](tm231749d1_ex99-1img016.jpg)

IMM - ONC - 01 Anti IL - 38 Antibody Copyright© 2023 Immunome, Inc. All rights reserved.

![](tm231749d1_ex99-1img017.jpg)

IND filing anticipated mid 2023 IMM - ONC - 01 Anti IL - 38 Antibody Anti IL - 38 Antibody Therapy has Potential to Be an Important Advancement in Cancer Care 17 Copyright© 2023 Immunome, Inc. All rights reserved. Blocking IL - 38 leads to tumor control in preclinical in vivo testing in two different models\* IL - 38 dampens immune response to tumors in preclinical testing\* IL - 38, a novel cancer target, identified by head & neck cancer patient antibody response \*Immunome internal data 01 02 03 04 IL - 38 Appears to Suppress Anti - Tumor Immunity Potential indications include squamous cell carcinomas, such as head & neck, gastroesophageal and lung

![](tm231749d1_ex99-1img018.jpg)

Growing Evidence of IL - 38 as a Key Immune Modulator 18 Copyright© 2023 Immunome, Inc. All rights reserved. Takeda et al. PLoS One (2017)

![](tm231749d1_ex99-1img019.jpg)

IL - 38 is Expressed in Multiple Tumors 2 IL - 38 Protein Expression In HNSCC Aligns With Transcriptional Data 3 → Tumor versus Healthy Adjacent Tissue Expression (% of Patient Expression) → Pathology Scoring of Individual Patient Samples by Stage IL - 38 Expression in Solid Tumors 19 Copyright© 2023 Immunome, Inc. All rights reserved. D o c 0 3 1 4 4 4 R n s 0 5 0 2 6 8 D o c 1 8 0 3 7 0 D o c 1 6 0 1 1 8 D o c 1 7 0 3 0 8 R l a 1 5 0 0 7 6 R l a 0 6 0 0 7 7 R l a 0 2 0 0 5 4 R l a 0 9 0 0 3 7 R l a 1 1 0 0 2 6 R l a 1 3 0 0 4 2 R l a 1 3 0 0 3 0 R l a 1 4 0 0 6 5 R l a 0 1 0 0 8 8 D o c 0 9 0 2 4 7 D o c 0 6 2 3 0 2 D o c 0 6 2 2 3 8 D o c 0 6 2 3 0 7 D o c 0 3 0 4 6 3 D o c 1 3 0 4 7 2 D o c 1 3 0 4 9 8 D o c 1 1 0 1 9 3 D o c 0 2 2 7 8 2 D o c 1 4 0 0 7 3 D o c 1 4 0 1 4 8 D o c 0 6 2 3 0 5 D o c 0 9 0 1 4 9 D o c 0 7 0 3 6 9 D o c 1 4 0 0 4 5 D o c 1 0 0 3 0 8 D o c 1 8 0 0 7 4 R l a 0 1 0 1 6 2 R l a 1 3 0 0 5 8 R l a 0 1 0 1 7 3 R l a 1 3 0 0 6 5 R l a 0 2 0 0 6 3 R l a 0 5 0 0 0 7 R l a 0 2 0 0 5 8 D o c 0 6 1 8 3 0 D o c 0 6 0 6 2 1 R n s 0 2 0 6 6 6 D o c 1 4 0 1 8 5 D o c 0 3 1 8 0 8 D o c 0 7 0 3 1 0 D o c 1 4 0 0 5 2 D o c 1 8 0 3 6 5 D o c 1 6 0 0 7 7 D o c 0 3 0 4 5 6 D o c 0 6 2 2 9 8 R l a 0 1 0 0 0 5 R l a 1 0 0 0 1 8 R l a 1 0 0 0 1 0 R l a 1 5 0 0 9 8 R l a 0 1 0 0 5 9 R l a 0 2 0 0 5 3 R l a 0 1 0 1 0 7 R l a 1 5 0 0 9 2 R l a 0 1 0 1 0 9 R l a 0 1 0 1 0 6 R l a 0 5 0 2 7 2 R l a 0 1 0 1 4 5 R l a 0 6 0 0 2 4 R l a 0 1 0 0 7 2 R l a 0 2 0 2 5 8 R l a 0 1 0 1 4 4 R l a 0 6 0 0 8 8 R l a 0 2 0 0 6 0 R l a 0 6 0 5 9 6 D o c 1 4 0 1 2 4 D o c 1 8 0 2 6 8 0 2 4 6 Stage I Stage II Stage III Stage IVA Weak Moderate Strong Negative SCC of Max. Sinus Stage III. T3N0M0 SCC of Tongue root Stage II. T2N0M0 ACC of Parotid Stage II. T2N0M0 Isotype Control Anti IL - 38 (Immunome Clone) Weak Moderate Strong Head & Neck Lung, Squamous Esophagus Cervix Skin Lung, Adeno 23% 53% 41% 48% 25% 14% 30% 9% Bladder Prostate log2TPM log2TPM 1. Source: Tempus Real - World Data 2. Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset 3. Immunome Internal Data IL - 38 Expression Confirmed in Multiple Tumors of High Unmet Medical Need 1

![](tm231749d1_ex99-1img020.jpg)

IL - 38 Overexpression Inhibits Infiltration of T cells into Tumors In Vivo High IL - 38 Expression is Associated with Reduced Immune Cell Infiltration\* → IL - 38 high tumor samples correlate with reduced infiltration of multiple immune subsets, especially in lung, head & neck, and gastroesophageal cancers IL - 38 Expression is Associated with Reduced Immune Cell Infiltration 20 Copyright© 2023 Immunome, Inc. All rights reserved. \*Immunome analysis of the Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset Similar findings were also confirmed in real - world data (Tempus) - 0 . 6 - 0 . 4 - 0 . 2 0 . 0 0 . 2 0 . 4 0 . 6 SKCM CESC LUAD ESCA LUSC HNSC T Cells - 0 . 3 - 0 . 2 - 0 . 1 0 . 0 0 . 1 0 . 2 0 . 3 SKCM CESC LUAD ESCA LUSC HNSC B Cells - 0 . 6 - 0 . 4 - 0 . 2 0 . 0 0 . 2 0 . 4 0 . 6 SKCM CESC LUAD ESCA LUSC HNSC Macrophages - 0 . 5 0 - 0 . 2 5 0 . 0 0 0 . 2 5 0 . 5 0 SKCM CESC LUAD ESCA LUSC HNSC Monocytes - 0 . 2 - 0 . 1 0 . 0 0 . 1 0 . 2 SKCM CESC LUAD ESCA LUSC HNSC NK Cells SKCM CESC LUAD ESCA LUSC HNSC Key D e c r e a s e d i n I L - 3 8 H i g h T u m o r s I n c r e a s e d i n I L - 3 8 H i g h T u m o r s ImSig Score Difference (IL-38 High minus IL-38 low) Kinoshita et al, Cancer Immunol. Immunother .(2021) 70:123 1200 1000 800 600 400 200 CD3 (/mm 2) LLC - vector LLC – IL38 800 700 600 500 400 300 200 100 0 CD8 (/mm 2) LLC - vector LLC – IL38

![](tm231749d1_ex99-1img021.jpg)

IMM - ONC - 01 Anti IL - 38 Antibody Blocking IL - 38 Leads to Tumor Control in Two Different Tumor Models 1 21 Copyright© 2023 Immunome, Inc. All rights reserved. Demonstration of Anti - Tumor Activity (B16F10 Model) Induction of Anti - Tumor Memory (EMT6 Model) → Immunologically cold tumor model → IMM - ONC - 01 significantly inhibits B16.F10 tumor growth in vivo at 10 and 50 mg/Kg doses → ~40% response rate upon treatment with IMM - ONC - 01 → Animals with complete cures resistant to tumor re - challenge – Strongly suggests immunological memory – Consistent with indirect effect on T cells 0 10 20 30 40 0 50 100 Day % S u r v i v a l IMM-ONC-01 Vehicle control 5 10 15 20 25 0 250 500 750 1000 Day T u m o r V o l u m e M e a n ± S E M (m m 3) Vehicle control IMM-ONC-01 1. AACR - NCI - EORTC Molecular Targets & Cancer Therapeutics Meeting, October 2021 (https://doi.org/10.1158/1535 - 7163.TARG - 21 - LBA022) Isotype IMM - ONC - 01 50 10 50 mg/Kg Q3D \* p < 0.05

![](tm231749d1_ex99-1img022.jpg)

IL - 38 and Potential Combinations Mechanistic Rationales for Both Chemotherapy and Immune Checkpoint Combinations 22 Copyright© 2023 Immunome, Inc. All rights reserved. Tumor Cells Can Secrete IL - 38 Upon Apoptosis Induction IL - 38 Levels Correlate with PD - L1 Expression → IL - 38 secretion associated with apoptotic cell death 1 → Acts during tissue damage to limit unwanted immune activation 2 → Human tumor cells from multiple tumor types secrete IL - 38 during apoptosis in vitro → PD - L1 positive cases exhibited higher levels of IL - 38 expression than PD - L1 negative cases (P < 0.0001) 1. Mora et al, 2016. J. Cell Mol. Cell Biol. 2016;8 (5):426 2. Wei et al. J. Cell Mol. Med. 2016;00 :1 M e d i a 0 h 4 h 1 6 h 0 h 4 h 1 6 h 0 h 4 h 1 6 h 0 h 4 h 1 6 h 0 h 4 h 1 6 h 0 h 4 h 1 6 h 0 1000 2000 3000 4000 5000 I L - 3 8 (p g / m L) 786O HuH7 MDA MB231 SKMEL28 SKOV3A549 Lung Renal Liver Breast Skin Ovarian Takeda et al. PLoS One (2017)

![](tm231749d1_ex99-1img023.jpg)

23 IMM - ONC - 01 Program Summary Copyright© 2023 Immunome, Inc. All rights reserved. → In vitro and in vivo preclinical research confirms antitumor activity of ONC - 01 in solid tumors as a monotherapy → Gene expression profiling of patient tumors suggest normal IL - 38 biology is co - opted by tumors of squamous origin to suppress immune infiltration 1 → ONC - 01 exhibits favorable pharmacokinetic profile → ONC - 01 is well tolerated in GLP toxicology studies → Potential indications include s quamous cell carcinomas, such as head & neck, gastroesophageal and lung → IND submission anticipated in mid 2023 1. Tempus Database 2. Immunome Internal Data Targets IL - 38, a Novel Immune Modulator IL - 38 Protein Expression In HNSCC Aligns With Transcriptional Data 2 SCC of Tongue root Stage II. T2N0M0 Isotype Control Anti IL - 38 (Immunome Clone) SCC of Max. Sinus Stage III. T3N0M0

![](tm231749d1_ex99-1img024.jpg)

ONCOLOGY Platform and Research Pipeline Copyright© 2023 Immunome, Inc. All rights reserved.

![](tm231749d1_ex99-1img025.jpg)

25 Untapped Biology and Novel Therapeutic Targets Copyright© 2023 Immunome, Inc. All rights reserved. TROP2 EGFR CD20 CD19 HER2 Novel targets have the potential to lead to more effective antibody - based therapies (including ADC, TCE & CAR - T modalities) Current Therapies are Based on Limited Knowledge of the Diversity and Complexity of Human Tumors TOMORROW TODAY

![](tm231749d1_ex99-1img026.jpg)

Preclinical efficacy testing Impact of targeting ectopic EPN1: Mechanism of Action and anti - tumor effect EPN1 ectopically expressed on surface of cancer cells and exosomes in preclinical testing EPN1, a novel cancer target, identified by H&N cancer patient antibody response → Preliminary Immunome data suggest Melanoma, Breast, Lung, Genitourinary, and Liver Cancers ectopically express EPN1 → Potential modalities include standard mAb and TCE IMM20059 Anti - EPN1 Antibody Antibody Targeting Ectopically Expressed Protein 26 Copyright© 2023 Immunome, Inc. All rights reserved. Ectopic EPN1 01 02 03 04

![](tm231749d1_ex99-1img027.jpg)

Tumor Growth Anti - tumor Immune Response → Combination of IMM20059 + atezolizumab leads to significant tumor control in the B16.F10 model as compared to either therapy alone → IMM20059 + atezolizumab treatment of B16.F10 tumor - bearing mice leads to upregulation of intra - tumoral inflammatory chemokines Anti - EPN1 Antibody in Combination with PD - L1 Enhances Anti - Tumor Efficacy 1 27 Copyright© 2023 Immunome, Inc. All rights reserved. \* p < 0.05; \*\*\*p < 0.001 by one - way ANOVA with Dunnett's post - hoc test \* p < 0.05 by one - way ANOVA with Dunnett's post - hoc test 0 5 10 0 500 1000 1500 2000 Day M e a n T u m o r V o l u m e ± S E M (m m 3) hIgG1 Isotype - 25 mg/kg Atezolizumab - 12.5 mg/kg IMM20059 - 12.5 mg/kg Atezolizumab (12.5 mg/kg) + IMM20059 (12.5 mg/kg) 1st dose Last dose 0 5 10 0 500 1000 1500 2000 Day M e a n T u m o r V o l u m e ± S E M (m m 3) hIgG1 Isotype - 25 mg/kg Atezolizumab - 12.5 mg/kg IMM20059 - 12.5 mg/kg Atezolizumab (12.5 mg/kg) + IMM20059 (12.5 mg/kg) 1st dose Last dose 0 5 10 0 500 1000 1500 2000 Day M e a n T u m o r V o l u m e ± S E M (m m 3) hIgG1 Isotype - 25 mg/kg Atezolizumab - 12.5 mg/kg IMM20059 - 12.5 mg/kg Atezolizumab (12.5 mg/kg) + IMM20059 (12.5 mg/kg) 1st dose Last dose IMM20059 (12.5 mg/kg) + Atezolizumab (12.5 mg/kg) I s o t y p e A t e z o l i z u m a b I M M 2 0 0 5 9 I M M 2 0 0 5 9 + A t e z o l i z u m a b Eotaxin G-CSF IFNγ IL-1α IL-6 IL-9 IL-10 CXCL10 (IP-10) CXCL1 (KC) CCL2 (MCP-1) CXCL9 (MIG) CCL3 (MIP-1α) CCL4 (MIP-1β) CXCL2 (MIP2) CCL5 (RANTES) VEGF Luminex analysis of intratumoral cytokines: Fold change over isotype control F o l d C h a n g e O v e r I s o t y p e G r o u p 2 4 6 \* \*\*\* \*\*\* \*\*\* 1. SITC 37 th Annual Meeting (https:// jitc.bmj.com /content/10/Suppl_2/A858) Ectopic expression of EPN1 may also enable efficacious targeting through use of T cell engagers

![](tm231749d1_ex99-1img028.jpg)

Correlations lead to identification of actionable public targets Immunome Discovery Engine 2.0: Context Dependent Drug Discovery Beyond Memory B - cells: What Other Immune Components Play a Role in Response? 28 Copyright© 2023 Immunome, Inc. All rights reserved. Leverage big data sets and complex analyses to visualize patient responses Multi - dimensional analysis yields extensive immune response data Capture immune responses across diverse patient populations and tissues Understanding The Interplay Between the Tumor and its Microenvironment Cabrita et al, Nature (2020) 01 02 03 04 Platform Applicable Beyond Solid Tumors

![](tm231749d1_ex99-1img029.jpg)

29 Financial Overview and Intellectual Property Snapshot Copyright© 2023 Immunome, Inc. All rights reserved. → Cash at least through 3Q 2024 → Capital efficient business model – partnerships and proprietary programs → Eligible for additional platform access payments during the research term in the AbbVie Collaboration National phase filling decisions crafted broadly based upon anticipated indications Active ongoing research likely to generate additional IP, including trade secrets and patent applications around platform and pipeline Antibodies for lead oncology programs and uses thereof covered by International patent applications; projected expirations in 2039 and beyond Platform technology and discovery engine protected through base patents and know - how exclusively - licensed by Immunome and further patents and trade secrets owned by Immunome Antibodies targeting SARS - CoV - 2 epitopes and 2 or 3 - antibody cocktails covered by International patent applications that include use for treatment of SARS - CoV - 2 infection Strategy incorporates both trade secrets around platform enhancements and filing of patent applications upon validation of new antibody targets and delineation of proposed therapeutic hypotheses

![](tm231749d1_ex99-1img030.jpg)

Immunome "At a Glance" Disruptive Technology Leveraging Human Immune Response 30 Copyright© 2023 Immunome, Inc. All rights reserved. → Interrogates memory B cells, the most educated component of the human immune system → Potential across multiple therapeutic areas Patient Informed Drug Discovery Engine → AbbVie multi - year research collaboration (up to 10 novel antibody - target pairs) → U.S. DoD JPEO - CBRND in collaboration with DHA (Antibody cocktail for SARS - CoV - 2) Significant Partnering Potential → Antibody targeting IL - 38, a novel context dependent immune modulator in multiple solid tumors with poor prognosis → IND submission anticipated mid - 2023 Lead Oncology Program IMM - ONC - 01 → Antibody targeting EPN1, an ectopically expressed target → Multiple additional novel targets enabling next - generation modalities (ADCs, T - cell engagers) Rich Research Pipeline → Value creation through partnerships and proprietary programs → Strong cash position; runway through at least 3Q 2024 Capital - Efficient Business Strategy

![](tm231749d1_ex99-1img031.jpg)

IMM - BCP - 01 Copyright© 2023 Immunome, Inc. All rights reserved. Collaboration with U.S. DoD & DHA for IMM - BCP - 01 Program, Awarded Up to $17.6M in Funding\* Phase 1b Topline Results \* OTA: W911QY - 20 - 9 - 0019

![](tm231749d1_ex99-1img032.jpg)

PHASE 1B Identified Antibodies from SARS - CoV - 2 patient memory B cell response IMM - BCP - 01 three antibody cocktail designed to retain efficacy against emerging variants In vitro preclinical neutralization of variants that have emerged over time 1 In vitro neutralization translates into i n vivo efficacy in infected hamster models 1 32 IMM - BCP - 01: Three Antibody Cocktail for the Treatment of COVID - 19 Copyright© 2023 Immunome, Inc. All rights reserved. Vehicle IMM - BCP - 01\* IMM - BCP - 01 Neutralizes Broad Array of Variants 1. IMM20190 not included in testing; https:// investors.immunome.com /immunome - announces - data - demonstrating - covid - 19 - antibody - cocktail - potently - clears - omicron - ba - 1 - variant - in - hamster - model - and - reta ins - activity - against - ba - 2 - subvariant/ 01 02 03 04

![](tm231749d1_ex99-1img033.jpg)

33 IMM - BCP01 - 001 Clinical Study Top Line Results: Safety and Pharmacokinetics Copyright© 2023 Immunome, Inc. All rights reserved. → Phase 1b, 2:1 randomization (n = 9; 6 active: 3 placebo) → Single dose of cocktail (600 mg total) administered as an intravenous infusion → No significant treatment - related AEs reported → PK profiles exhibits classic IgG1 features → C max averaged 92 ug/mL among mAbs → Apparent Half life ~ 23 days (IMM20184, IMM20190) → Apparent Half life – 11 days (IMM20253) – IMM20253 also exhibits the highest binding to the RBD of SARS - CoV - 2 in preclinical testing – IMM20253 appears to exhibit enhanced antigen dependent PK at the dose administered 1000 10000 100000 1000000 0 200 400 600 800 1000 1200 1400 M e a n S e r u m C o n c e n t r a t i o n (n g / m L) Time Post-Infusion (hr) IMM-BCP-1001 -Mean Serum Concentration Comparison -Cohort 1 IMM20184 IMM20190 IMM20253 Mean Serum Concentration (ng/mL) Time Post - Infusion (Hr) IMM20184 IMM20190 IMM20253 0 200 400 600 800 1000 1200 140 0 1000000 100000 10000 1000 We have decided to seek a partner in order to continue the trial and for any further development activities

![](tm231749d1_ex99-1img034.jpg)

34 IMM - BCP - 01 Neutralizes Virus Utilizing Different Mechanisms Copyright© 2023 Immunome, Inc. All rights reserved. Pre - fusion spike (S1 + S2) Post - fusion spike (S2) DIRECT ACE2 BLOCKADE ANTIBODY INDUCED CONFORMATIONAL CHANGE DESTABILIZES SPIKE PROTEIN\* ACE2 1 2 IMM20253 IMM20190 + IMM20184 \* Nikitin et al Sci Immunol; 2022 (https:// www.science.org / doi /10.1126/sciimmunol.abl9943) Structural analysis demonstrates IMM20253 binding induces unfolding of spike trimer → Increasing antibody:trimer ratio results in dissociation of trimer into soluble antibody - bound spike monomers → IMM20253+IMM20184 exhibits enhanced activity in SARS - CoV - 2 infected hamsters Ab - bound trimer Ab - bound monomer